Showing results (201-210 of 534) with videos related to

Sort By:
Pageof 54
The American Journal of Cardiology|July 17, 2007
Impact of sex, metabolic syndrome, and diabetes mellitus on cardiovascular eventsKoon-Hou Mak, Stefan Ma, Derrick Heng, et al.
Health Affairs (Project Hope)|March 9, 2004
Inside the triple helix: technology transfer and commercialization in the life sciencesEric G Campbell, Joshua B Powers, David Blumenthal, et al.
Annals of Internal Medicine|November 17, 2010
The regional extension center program: helping physicians meaningfully use health information technologyEmily Maxson, Sachin Jain, Mat Kendall, et al.
Physiological Genomics|March 20, 2003
Proteomic approach to coronary atherosclerosis shows ferritin light chain as a significant marker: evidence consistent with iron hypothesis in atherosclerosisSun-Ah You, Stephen R Archacki, George Angheloiu, et al.
The American Journal of Cardiology|August 29, 2003
Peripheral vascular disease and one-year mortality following percutaneous coronary revascularizationJohn H Chiu, Eric J Topol, Patrick L Whitlow, et al.
The American Journal of Cardiology|February 22, 2005
Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial)Derek P Chew, A Michael Lincoff, Hitinder Gurm, et al.
BMC Medicine|December 7, 2017
Spectrum of mutations in monogenic diabetes genes identified from high-throughput DNA sequencing of 6888 individualsVikas Bansal, Johann Gassenhuber, Tierney Phillips, et al.
Yonsei Medical Journal|April 24, 2002
Local delivery of nitric oxide from an eluting stent to inhibit neointimal thickening in a porcine coronary injury modelJung Han Yoon, Chiung Jen Wu, James Homme, et al.
American Heart Journal|June 1, 2002
Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET)A Michael Lincoff, Neal S Kleiman, Kandace Kottke-Marchant, et al.
JAMA|November 19, 2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trialSteven R Steinhubl, Peter B Berger, J Tift Mann, et al.
Pageof 54